Keenova Reports First Quarter 2026 Financial Results

Strong First-Quarter Performance Driven by Acthar® Gel1 and XIAFLEX®2 Pipeline Development, Synergy Plan Remain on Track Reaffirms 2026 Net Sales Guidance of $1.94 Billion to $2.00 Billion and Adjusted EBITDA Guidance of $730 Million to $760 Million Conference Call and Webcast Today at...